Advice
in the absence of a submission from the holder of the marketing authorisation:
fulvestrant (Faslodex®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- fulvestrant (Faslodex)
- SMC ID:
- 1294/17
- Indication:
- Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 December 2017